Endocrine Cancers
An Introduction to Endocrine Cancers
The management of NETs is challenging & very difficult to study, due to many centres lacking experience in their management, survival rates remaining low and the overall rarity of the tumours themselves. However, recent developments in tumour grading, diagnostic biomarkers, radionuclide imaging and the development of somatostatin analogues, molecular targeted therapies, locoregional therapy and immunotherapies have improved outcomes in NETs. Further studies aimed at understanding the pathogenesis of NETs remain an important unmet need.
Expert video highlights and insights from the conference hub and comprehensive peer-reviewed articles from our journal portfolio provide updates on the ever-changing landscape.